Literature DB >> 15772192

Patent foramen ovale and the risk of stroke: smoking gun guilty by association?

P Amarenco1.   

Abstract

Entities:  

Mesh:

Year:  2005        PMID: 15772192      PMCID: PMC1768821          DOI: 10.1136/hrt.2004.052241

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  9 in total

1.  Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause.

Authors:  K Berthet; T Lavergne; A Cohen; L Guize; M G Bousser; J Y Le Heuzey; P Amarenco
Journal:  Stroke       Date:  2000-02       Impact factor: 7.914

2.  Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart.

Authors:  F Ravelli; M Allessie
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

3.  Prevalence of patent foramen ovale in patients with stroke.

Authors:  P Lechat; J L Mas; G Lascault; P Loron; M Theard; M Klimczac; G Drobinski; D Thomas; Y Grosgogeat
Journal:  N Engl J Med       Date:  1988-05-05       Impact factor: 91.245

4.  Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.

Authors:  J L Mas; C Arquizan; C Lamy; M Zuber; L Cabanes; G Derumeaux; J Coste
Journal:  N Engl J Med       Date:  2001-12-13       Impact factor: 91.245

5.  Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies.

Authors:  J R Overell; I Bone; K R Lees
Journal:  Neurology       Date:  2000-10-24       Impact factor: 9.910

6.  Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study.

Authors:  Shunichi Homma; Ralph L Sacco; Marco R Di Tullio; Robert R Sciacca; J P Mohr
Journal:  Circulation       Date:  2002-06-04       Impact factor: 29.690

Review 7.  Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Gregory W Albers; Pierre Amarenco; J Donald Easton; Ralph L Sacco; Philip Teal
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

8.  Patent foramen ovale: is stroke due to paradoxical embolism?

Authors:  D Ranoux; A Cohen; L Cabanes; P Amarenco; M G Bousser; J L Mas
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

9.  Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography.

Authors:  L Cabanes; J L Mas; A Cohen; P Amarenco; P A Cabanes; P Oubary; F Chedru; F Guérin; M G Bousser; J de Recondo
Journal:  Stroke       Date:  1993-12       Impact factor: 7.914

  9 in total
  5 in total

1.  Prevalence and characteristics of right-to-left shunt in migraine with aura: a survey on 120 Italian patients.

Authors:  L Caputi; Domenico D'Amico; S Usai; L Grazzi; E A Parati; G Bussone
Journal:  Neurol Sci       Date:  2009-05       Impact factor: 3.307

Review 2.  Point-of-Care-Testing in Acute Stroke Management: An Unmet Need Ripe for Technological Harvest.

Authors:  Dorin Harpaz; Evgeni Eltzov; Raymond C S Seet; Robert S Marks; Alfred I Y Tok
Journal:  Biosensors (Basel)       Date:  2017-08-03

3.  Evaluation of patent foramen ovale in young adults with cryptogenic stroke.

Authors:  Hossein Ali Ebrahimi; Akbar Hamzeaie Moghadam; Esmaeel Aredestani
Journal:  ARYA Atheroscler       Date:  2011

4.  Decline in mean platelet volume in patients with patent foramen ovale undergoing percutaneous closure.

Authors:  Barış Düzel; Nihan Kahya Eren; Rida Berilgen; Uğur Kocabaş; Mustafa Gönençer; Cem Nazli; Oktay Ergene
Journal:  Cardiovasc J Afr       Date:  2014 Jul-Aug       Impact factor: 1.167

Review 5.  B-Type Natriuretic Peptide as a Significant Brain Biomarker for Stroke Triaging Using a Bedside Point-of-Care Monitoring Biosensor.

Authors:  Dorin Harpaz; Raymond C S Seet; Robert S Marks; Alfred I Y Tok
Journal:  Biosensors (Basel)       Date:  2020-08-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.